3 results
Approved WMOCompleted
* Primary objective: To determine the effect of 78-weeks therapy with omalizumab compared to placebo on the number of sub-epithelial eosinophils, a marker of airway inflammation, in patients with persistent moderate to severe allergic asthma. *…
Approved WMORecruiting
To compare effectiveness, costs and patient preferences in the treatment of sBCC with fractionated 5-ALA 20% PDT versus MAL PDT in 2 sessions.
Approved WMORecruiting
1. Assess the effect of Ru-106 brachytherapy applicators on tumor dimensions. 2. Assess the value of DWI and PWI as an early predictor of therapy response after Ru-106 brachytherapy in UM.